asa glp-1 agonists Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 GLP-1 RA guidance roundup -

Never Share a Pen: Pen-sharing poses a risk of infection

[DOI] [PubMed] [Google Scholar] 64.Astrup A., Rossner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M

To address this, manufacturers have sought partnerships with major pharmacy benefit managers

Presented at the 2011 International Diabetes Federation World Diabetes congress

Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market

TABLE 1 Summary of case reports of GLP-1 receptor agonists-induced acute pancreatitis reported in the literature